Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301590 | 0.96 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1HSP90B1MCHR1ROCK1 | |
| SCHEMBL30301565 | 0.89 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1HSP90B1ROCK1ROCK2 | |
| SCHEMBL30301601 | 0.88 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1HSP90B1ROCK1ROCK2 | |
| SCHEMBL25205369 | 0.87 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1HSP90B1MCHR1ROCK1 | |
| SCHEMBL30462406 | 0.87 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1HSP90B1MCHR1ROCK1 | |
| SCHEMBL30301547 | 0.85 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSP90B1MCHR1ROCK1 | |
| SCHEMBL25222618 | 0.85 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSP90B1MCHR1ROCK1 | |
| SCHEMBL25221649 | 0.80 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1HSP90B1MCHR1ROCK1 | |
| SCHEMBL30368298 | 0.80 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1HSP90B1MCHR1ROCK1 | |
| SCHEMBL31281713 | 0.79 | PARP15 (0.36) | HSP90AA1HSP90AB1HSP90B1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | claimed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4157463-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-04-05 | — | — | EP | claimed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4157463-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | HSP90AA1 2502/4885HSP90AB1 1847/4885HSP90B1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.